Human LINGO-2
Alexa Fluor® 700-conjugated Antibody
Monoclonal Mouse IgG₂A Clone # 382007
Catalog Number: FAB36791N
100 µg

DESCRIPTION

Species Reactivity  Human
Specificity  Detects human LINGO-2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human LINGO-1 is observed.

Source  Monoclonal Mouse IgG₂A Clone # 382007

Purification  Protein A or G purified from hybridoma culture supernatant

Immunogen  Mouse myeloma cell line NS0-derived recombinant human LINGO-2 Cys28-Leu542 Accession # Q7L985

Conjugate  Alexa Fluor 700
Excitation Wavelength: 675-700 nm
Emission Wavelength: 723 nm

Formulation  Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.

*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

<table>
<thead>
<tr>
<th>Recommended Concentration</th>
<th>Sample</th>
</tr>
</thead>
</table>
|                         | Flow Cytometry
| 0.25-1 µg/10⁶ cells       | A549 human lung carcinoma cell line and and HEK293 human embryonic kidney cell line either transfected with human LINGO-2 and eGFP |

PREPARATION AND STORAGE

Shipping  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage  Protect from light. Do not freeze.
- 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Human LINGO-2 (LRR and Ig domain-containing, Nogo Receptor-interacting protein 2; also known as Leucine-rich repeat neuronal 6C (LRRN6C) or LERN3), type I transmembrane protein in the neuronal leucine-rich repeat family. These proteins have a signal peptide, 12 extracellular leucine-rich repeats flanked by N-terminal and C-terminal cysteine-rich sequences, an immunoglobulin-like domain, a transmembrane domain and a short cytoplasmic tail. An alternate start site may exist at Met148 of the precursor. Human LINGO-2 is a highly conserved, 606 amino acid protein that shares 99% and 98% aa sequence identity with canine and mouse LINGO-2, respectively. LINGO-2 presumably functions outside the CNS with little involvement by p75/NgR1.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license for this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300, Fax: (541) 335-0354.